MedPath

Efficacy of Proton Pump Inhibitor in Prevention of Clopidogrel-related Peptic Ulcer

Phase 2
Completed
Conditions
Peptic Ulcer
Interventions
Registration Number
NCT01138969
Lead Sponsor
Kaohsiung Veterans General Hospital.
Brief Summary

Proton Pump Inhibitors (PPI) can prevent the recurrence of peptic ulcer in clopidogrel users.

Detailed Description

The aim of the prospective, randomized study is to investigate the efficacy of PPI in prevention of ulcer recurrence for clopidogrel users. We plan to enroll 300 clopidogrel users without baseline gastroduodenal ulcer at initial endoscopy. The patients will be randomly assigned to receive either (1) esomeprazole (20 mg qd) plus clopidogrel or (2) clopidogrel treatment alone for 6 months. The ulcer recurrence rate between the treatment groups will be compared.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
165
Inclusion Criteria
  • We plan to enroll 300 clopidogrel users without baseline gastroduodenal ulcer at initial endoscopy. The patients will be randomly assigned to receive either (1) esomeprazole (20 mg qd) plus clopidogrel or (2) clopidogrel treatment alone for 6 months.
Exclusion Criteria
  • 1.serious disease 2.refuse informed consent

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Esomeprazole plus clopidogrel groupesomeprazoleesomeprazole (20 mg qd) plus clopidogrel (75 mg qd) for 6 months
Primary Outcome Measures
NameTimeMethod
Recurrent Peptic Ulcer6 months

Number of participants with recurrent peptic ulcer within 6 months

Secondary Outcome Measures
NameTimeMethod
Peptic Ulcer Bleeding6 months

participants with peptic ulcer bleeding within 6 months

Trial Locations

Locations (1)

Kaohsiung Veterans General Hospital

🇨🇳

Kaohsiung, Taiwan

© Copyright 2025. All Rights Reserved by MedPath